SLE Risk Scoring With EC4d, BC4d, and ANA Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring Systemic Lupus Erythematosus (SLE) are unreliable due to the variability of symptoms and lack of definitive tests, leading to misdiagnosis and inadequate treatment, and existing diagnostic markers like ANA and anti-dsDNA have limited sensitivity and specificity.
Innovation Solution
A method involving the calculation of an SLE risk score based on levels of erythrocyte C4d (EC4d), B-cell C4d (BC4d), and anti-nuclear antibodies (ANA) markers, optionally with additional rule-out markers, using logistic regression analysis to adjust and combine marker levels for improved diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic criteria (11 criteria) are used for diagnosing SLE, then diagnosis can be made based on available clinical manifestations, but diagnostic accuracy is reduced due to symptom variability and lack of definitive tests
Solution Approach 1:
The patent transforms the diagnostic approach by changing from qualitative clinical criteria assessment to quantitative biomarker measurement. Specific parameters measured include complement activation products (C3d, C4d), immune complex levels, and autoantibody titers. This parameter transformation enables objective, numerical diagnosis rather than subjective clinical judgment, directly resolving the contradiction between diagnostic reliability and complexity.
Solution Approach 2:
The patent introduces complement activation products and immune complex measurements as intermediary biomarkers that mediate between clinical symptoms and definitive diagnosis. These intermediaries provide measurable evidence of disease pathophysiology, serving as objective bridges between non-specific clinical manifestations and confirmed SLE diagnosis, thereby improving diagnostic accuracy without requiring complex multi-criteria evaluation.
2Productivity
If liberal standards are applied for determining the presence or absence of criteria, then more patients can be diagnosed, but false positive diagnoses increase
Solution Approach 1:
The patent implements feedback through quantitative biomarker thresholds and risk scoring systems. Measured values of complement activation products, immune complexes, and autoantibodies are compared against established thresholds to provide objective feedback on disease likelihood. This feedback mechanism enables consistent application of diagnostic standards, preventing both over-diagnosis and under-diagnosis while maintaining high specificity through numerical criteria rather than subjective interpretation.
3Ease of operation
If individual marker levels (EC4d, BC4d, ANA) are used for diagnosis, then simple testing is performed, but sensitivity and specificity are limited
Solution Approach 1:
The patent merges multiple individual biomarker measurements into a comprehensive diagnostic profile. Instead of relying on single markers like ANA or anti-dsDNA alone, the method combines measurements of complement activation products (C3d, C4d), immune complexes, and various autoantibodies. This merging of multiple simple tests creates a powerful composite diagnostic tool that maintains operational simplicity while dramatically improving both sensitivity and specificity through the accumulation of diagnostic evidence from multiple sources.
Data Source
AI summary
Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, anti-nuclear antibodies (ANA), and optional rule-out markers.